Fertility
Are period tracking apps falling behind? Why GenAI is the missing piece

By Morgan Rose, Chief Science Officer at Ema
Period tracking apps have come a long way—from simple calendar-based logs to advanced cycle prediction tools.
But are these apps truly meeting women’s needs, or are they missing a critical opportunity?
The reality is that most period apps stop at data collection—they track symptoms but don’t translate that data into real-time, personalised support.
This is where Generative AI (Gen AI) can revolutionise the experience.
Why Period Apps Need Gen AI to Support Women
- Personalised, Real-Time Answers:
- Most period tracking apps offer static, one-size-fits-all predictions, but women’s cycles are dynamic. What happens when an app flags an irregular cycle? What if a user logs new, unexpected symptoms? Currently, many apps leave women to figure it out independently. Gen AI can change that by offering contextual explanations, possible causes, and next steps—without forcing users to Google symptoms or wait for a doctor’s appointment. A Journal of Medical Internet Research study found that women desire more personalised insights and guidance from period tracking apps, mainly for managing irregular cycles and understanding symptom patterns.
- A True Health Companion, Not Just a Calendar:
- Today, apps function as logbooks, not interactive guides. With Gen AI-powered assistants, users could have real-time conversations about their symptoms, emotional well-being, and health concerns. Instead of just logging mood swings, imagine an app recognising patterns and suggesting evidence-based strategies for symptom relief.
- Smarter Insights, Not Just Static Predictions:
- Period trackers use cycle history to make predictions, but what if a user skips logging for a few months? What if their symptoms shift due to lifestyle changes? Gen AI can fill the gaps by analysing past data, current trends, and external health factors (like stress, sleep, and exercise) to provide adaptive, real-time guidance. A survey analysis of menstrual cycle tracking technologies highlights the need for more sophisticated data analysis and personalised insights to improve the accuracy and effectiveness of period tracking.
- Bridging the Gap Between Tracking and Action:
- Most apps are passive—they remind users when their period is coming but don’t offer proactive health recommendations. Gen AI closes this gap by:
- Suggesting relevant health screenings based on symptoms
- Providing cycle-specific nutrition & lifestyle tips
- Helping users prepare for PMS symptoms before they hit
- Research suggests that women are increasingly using period tracking apps to manage their health proactively, and Gen AI can facilitate this by providing actionable recommendations and personalised guidance.
- Most apps are passive—they remind users when their period is coming but don’t offer proactive health recommendations. Gen AI closes this gap by:
Future-Proofing Femtech: AI as a Competitive Advantage
Apps that fail to integrate Gen AI risk becoming outdated and less engaging.
As women seek more intuitive, intelligent tools, those that leverage AI will become the go-to platforms for personalised reproductive health support.
AI-powered platforms like Ema are bridging this gap by ensuring personalised and medically relevant insights—helping women access smarter, more adaptive health support, no matter their background or needs.
The Bottom Line
Tracking is just the beginning—women deserve more than a digital calendar. Period apps that don’t evolve with Gen AI risk missing a major opportunity to support users in real-time.
It’s time to move beyond symptom tracking and into the AI-driven, personalised health guidance era.
Will your period app keep up?
Morgan Rose is a Certified Nurse Midwife, Women’s Health Nurse Practitioner, and International Board-Certified Lactation Consultant with over a decade of experience supporting women’s health.
As the Chief Science Officer at Ema, Morgan combines her expertise with her passion for empowering women. She lives in New York City with her spunky daughter and their beloved dog.
Learn more about her work with Ema here.
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Fertility
Femtech World reveals fertility innovation award shortlist

Femtech World is thrilled to reveal the shortlist for the Fertility Innovation Award.
The award, sponsored by FinDBest IVF, celebrates a pioneering product, service or initiative that is transforming fertility care and support.
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
This year’s nominees represent a remarkable breadth of approaches to fertility care: from clinic-floor breakthroughs to at-home hormone intelligence to truly borderless access.
Three companies made the cut, with each tackling a real, persistent barrier in reproductive health.
Congratulations to the shortlist and many thanks to everyone who entered.
Fertility Innovation Award Shortlist

HRC Fertility’s Needle-Free IVF is a pioneering advancement designed to transform one of the most challenging aspects of fertility treatment: daily hormone injections.
Developed by board-certified reproductive endocrinologist Dr Rachel Mandelbaum, this innovative approach reimagines how stimulation medications are delivered during IVF and egg freezing, dramatically improving the patient experience while maintaining the same trusted clinical outcomes.
Inspired by feedback from patients who struggled with the injection process, Dr Mandelbaum adapted an innovative drug-delivery system commonly used in other areas of medicine and applied it to reproductive care

Mira is a hormonal health technology company that provides lab-grade hormone testing and AI-driven insights to help women and couples understand their fertility.
The platform has already supported more than 200,000 couples on their fertility journeys worldwide, helping over 60,000+ users achieve pregnancy.
For some users, pregnancy rates have reached up to 89 per cent within six months, demonstrating how accurate hormone data can significantly improve fertility outcomes.

Founded in 2021 by Marija Skujina, a Certified Fertility Nurse Specialist accredited by the European Society of Human Reproduction and Embryology, with nearly 15 years of clinical experience at one of the world’s top IVF clinics, and having navigated her own fertility journey as a patient, Marija built the clinic she had always wished existed.
Plan Your Baby began with a bold, but simple mission – make best quality fertility and pregnancy available anywhere.
Plan Your Baby has created a new generation fertility and pregnancy clinic with patients accessing expert consultations remotely, while blood tests and ultrasound scans are available at over 450 locations across the UK, eliminating the exhausting travel burden that often forces people to take days off work, relocate appointments, or abandon treatment altogether
What happens now
The shortlist will be judged by a representative from category sponsor FindBestIVF, with the winner announced at a virtual event on June 19.
Winners will receive a trophy and be interviewed by a Femtech World journalist.
Entrepreneur4 weeks agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Entrepreneur3 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Diagnosis4 weeks agoNew meta-analysis further supports low re-excisions and high placement accuracy with the Magseed marker
Pregnancy4 weeks agoNIPT or NT scan? Why the 2026 evidence supports doing Both
Ageing4 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
News4 weeks agoResistance training has preventative effects in menopause, study finds
Insight3 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Wellness3 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage







